標(biāo)題: Titlebook: Deprenyl — Past and Future; W. Kuhn,P. Kraus,H. Przuntek Conference proceedings 1996 Springer-Verlag/Wien 1996 Alzheimer.Parkinson.diagnos [打印本頁] 作者: 尖酸好 時(shí)間: 2025-3-21 16:22
書目名稱Deprenyl — Past and Future影響因子(影響力)
書目名稱Deprenyl — Past and Future影響因子(影響力)學(xué)科排名
書目名稱Deprenyl — Past and Future網(wǎng)絡(luò)公開度
書目名稱Deprenyl — Past and Future網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Deprenyl — Past and Future被引頻次
書目名稱Deprenyl — Past and Future被引頻次學(xué)科排名
書目名稱Deprenyl — Past and Future年度引用
書目名稱Deprenyl — Past and Future年度引用學(xué)科排名
書目名稱Deprenyl — Past and Future讀者反饋
書目名稱Deprenyl — Past and Future讀者反饋學(xué)科排名
作者: 沒收 時(shí)間: 2025-3-21 23:14
https://doi.org/10.1007/978-3-322-90417-1ted as byproducts of normal and aberrant metabolic processes that utilize molecular oxygen. On the other hand, an increasing body of experimental data has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurological diseases. One of the receptor which is particularly作者: 不開心 時(shí)間: 2025-3-22 03:23
Die Business School im E-Zeitalterwhich does not induce MAO-B inhibition. The activity of MAO-B increases with age and the age related changes led to an overproduction of neurotoxic agents. The inhibition of the enzyme activity can play a preventive role against neurodegenerative brain disorders. The most widely used MAO-B inhibitor作者: 一個(gè)姐姐 時(shí)間: 2025-3-22 06:39 作者: Respond 時(shí)間: 2025-3-22 11:45
,New horizons in molecular mechanisms underlying Parkinson’s disease and in our understanding of theted as byproducts of normal and aberrant metabolic processes that utilize molecular oxygen. On the other hand, an increasing body of experimental data has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurological diseases. One of the receptor which is particularly作者: Obscure 時(shí)間: 2025-3-22 16:21
,The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (?)-deprenyl reseawhich does not induce MAO-B inhibition. The activity of MAO-B increases with age and the age related changes led to an overproduction of neurotoxic agents. The inhibition of the enzyme activity can play a preventive role against neurodegenerative brain disorders. The most widely used MAO-B inhibitor作者: Obscure 時(shí)間: 2025-3-22 17:46 作者: 輪流 時(shí)間: 2025-3-22 21:39 作者: Optimum 時(shí)間: 2025-3-23 04:27
https://doi.org/10.1007/978-3-322-90417-1ession of Parkinson’s disease (PD). Degeneration of nigrostriatal dopaminergic neurons is the primary histopathological feature of PD. Although many different hypotheses have been advanced, the cause of chronic nigral cell death and the underlying mechanisms remain elusive as yet. Therefore, there i作者: dry-eye 時(shí)間: 2025-3-23 07:07 作者: 脊椎動物 時(shí)間: 2025-3-23 11:38
Die Business School im E-Zeitalterplex mechanism. The MAO-B inhibition could result in a potentiation of the effect and the reduction of the dose of L-dopa, including the restoration of the sensitivity to L-dopa treatment, when the response to the drug has already been diminished or lost. Pre-treatment with (?)deprenyl prevent the e作者: Prophylaxis 時(shí)間: 2025-3-23 14:01
https://doi.org/10.1007/978-3-642-56707-0monoamine oxidase-B (MAO-B) inhibition. (?)-Deprenyl can also influence the process growth of some glial and neuronal populations and can reduce the concentrations of oxidative radicals in damaged cells at concentrations too small to inhibit MAO. In accord with the earlier work of others, we showed 作者: Crohns-disease 時(shí)間: 2025-3-23 19:03
Die Business School im E-Zeitalterr reviews possible roles of the metabolites of l-deprenyl in producing unwanted adverse side effects or in augmenting or mediating its clinically useful actions. Levels of l-amphctamine and l-methamphetamine likely to be reached, even with excessive intake of l-deprenyl, would be unlikely to produce作者: FRAUD 時(shí)間: 2025-3-23 23:01
Manfred Steiner,Sebastian Schneiderputative neuroprotective therapy. Clinical trials demonstrate that selegiline slows the rate of disease progression and delays the appearance of disability necessitating levodopa. However, confounding symptomatic effects have made it difficult to ascertain the presence of any direct neuroprotective 作者: sigmoid-colon 時(shí)間: 2025-3-24 02:31
Bewertung von E-Business Strategienng results could be observed both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one study of Tourette’s syndrome including attention hyperactivity disorders using an average dosis of 8.1 mg/ day. Controversial results were reported for Alzheimer’s disease. On the one作者: coagulate 時(shí)間: 2025-3-24 07:24
Simulation of Human Erythrocyte Metabolismike deprenyl, when given to rats in a dose selective for inhibition of MAO-B, it does not affect striatal extracellular fluid dopamine levels, but when administered chronically (21 days) it increased striatal microdialysate dopamine without reduction in deaminated metabolites. Similarly to deprenyl,作者: 反應(yīng) 時(shí)間: 2025-3-24 14:02
Modeling of Hsp70-Mediated Protein Refolding demonstrate the effects of neurotrophic factors on dopaminergic neurons in vitro and in vivo. At present this issue is predominantly investigated in basic neuroscientific research. Its possible future clinical relevance is discussed.作者: 允許 時(shí)間: 2025-3-24 18:26
Deprenyl — Past and Future978-3-7091-7494-4Series ISSN 0303-6995 作者: 審問 時(shí)間: 2025-3-24 21:36
Modeling of Hsp70-Mediated Protein Refolding demonstrate the effects of neurotrophic factors on dopaminergic neurons in vitro and in vivo. At present this issue is predominantly investigated in basic neuroscientific research. Its possible future clinical relevance is discussed.作者: 誘惑 時(shí)間: 2025-3-25 02:48 作者: 勾引 時(shí)間: 2025-3-25 05:41
https://doi.org/10.1007/978-3-7091-7494-4Alzheimer; Parkinson; diagnosis; dopamine; psychiatric disorder作者: Rejuvenate 時(shí)間: 2025-3-25 08:26
978-3-211-82891-5Springer-Verlag/Wien 1996作者: 稀釋前 時(shí)間: 2025-3-25 14:35
Journal of Neural Transmission. Supplementahttp://image.papertrans.cn/d/image/265790.jpg作者: 松果 時(shí)間: 2025-3-25 16:39 作者: Gratuitous 時(shí)間: 2025-3-25 22:33 作者: Habituate 時(shí)間: 2025-3-26 02:06 作者: moribund 時(shí)間: 2025-3-26 07:45
,The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (?)-deprenyl reseaplex mechanism. The MAO-B inhibition could result in a potentiation of the effect and the reduction of the dose of L-dopa, including the restoration of the sensitivity to L-dopa treatment, when the response to the drug has already been diminished or lost. Pre-treatment with (?)deprenyl prevent the e作者: aneurysm 時(shí)間: 2025-3-26 08:38 作者: magnanimity 時(shí)間: 2025-3-26 13:04 作者: 縮短 時(shí)間: 2025-3-26 16:52
,Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism ofputative neuroprotective therapy. Clinical trials demonstrate that selegiline slows the rate of disease progression and delays the appearance of disability necessitating levodopa. However, confounding symptomatic effects have made it difficult to ascertain the presence of any direct neuroprotective 作者: 神經(jīng) 時(shí)間: 2025-3-26 21:58 作者: 搜尋 時(shí)間: 2025-3-27 04:18 作者: 配偶 時(shí)間: 2025-3-27 05:19 作者: 圍巾 時(shí)間: 2025-3-27 13:23
Conference proceedings 1996rkinsonian drug called budipine with various modes of action also influencing altered non dopaminergic systems in Parkinson‘s disease. It is evident, that many questions on the cause, course and treatment of Parkinson‘s disease are still unanswered and therefore the ideal way to treat a parkinsonian patient remains to be defined.作者: Locale 時(shí)間: 2025-3-27 16:14
Manfred Steiner,Sebastian Schneiderntiapoptotic molecules which promote cell survival. Further delineation of the precise mechanism whereby selegiline induces this effect may permit for the development of enhanced neuroprotective benefits in PD patients.作者: aggravate 時(shí)間: 2025-3-27 21:16 作者: 芳香一點(diǎn) 時(shí)間: 2025-3-28 00:17
Die Business School im E-Zeitalterd l-methamphetamine have some qualitatively different actions than their disomer counterparts on EEG and cognitive functioning which might result in beneficial clinical effects and complement beneficial clinical actions of l-deprenyl itself.作者: dictator 時(shí)間: 2025-3-28 03:33
Bewertung von E-Business Strategienon of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.作者: 雕鏤 時(shí)間: 2025-3-28 08:56 作者: 修飾語 時(shí)間: 2025-3-28 14:29
The clinical potential of Deprenyl in neurologic and psychiatric disorders,on of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.作者: Self-Help-Group 時(shí)間: 2025-3-28 18:25
,New aspects of pathology in Parkinson’s disease with concomitant incipient Alzheimer’s disease,neurites. The specific lesional pattern of both illnesses accrues slowly over time. Presently available data support the view that fully developed Parkinson’s disease with concurring incipient Alzheimer’s disease is likely to cause impaired cognition.作者: pulse-pressure 時(shí)間: 2025-3-28 21:49 作者: floaters 時(shí)間: 2025-3-29 00:05 作者: concentrate 時(shí)間: 2025-3-29 03:27 作者: delusion 時(shí)間: 2025-3-29 09:27
Simulation of Human Erythrocyte Metabolism rasagiline (10.M) increased the percentage of tyrosine hydroxylase positive cells in a primary culture of rat fetal mesencephalic cells (6 days in culture). Rasagiline, but not deprenyl, also increased the number of neurons per field in this organotypic culture.作者: Gullible 時(shí)間: 2025-3-29 13:18 作者: 原告 時(shí)間: 2025-3-29 15:42
